Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Some better-ranked stocks in the broader medical space are TransMedix Group TMDX, Veracyte VCYT and Boston Scientific BSX. While TransMedix Group and Veracyte currently sport a Zacks Rank #1 (Strong ...

Four years later they launched FreeStyle Libre, a reimagined continuous glucose monitoring (CGM) system in which an even smaller sensor applied to a patient’s arm sends data directly to a ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...

Lingo is based on Abbott's FreeStyle Libre CGM technology. It can be used by consumers aged 18 years and older who are not on insulin. The system is worn on the back of the arm for up to 14 days.

Abbott (NYSE: ABT) today announced U.S. availability of Lingo™, the company's first continuous glucose monitoring system available without a prescription. The Lingo system includes a biosensor and a ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as ... every minute directly to the user's smartphone for up to 14 days, allowing them to adjust treatment as needed.

Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...

RHHBY's Accu-Chek Smartguide will provide several predictive features aimed at enhancing patient safety. However, the device ...

Compared with eating over 14+ hours per day, eating only within an 8-hour window over 3 days significantly increased time ...

Compared with eating over 14+ hours per day ... p.m., and last meal at 8 p.m. Glycemic measures were assessed with FreeStyle Libre continuous glucose monitors (CGMs). Physical activity levels ...